Average weight loss with tirzepatide -- the most powerful GLP-1 therapy available in Nigeria
Tirzepatide is a first-in-class dual-action therapy that targets two key metabolic pathways for unprecedented results.
Unlike semaglutide which targets only GLP-1, tirzepatide activates both GIP and GLP-1 receptors simultaneously. This dual mechanism delivers superior weight loss compared to single-pathway therapies.
In published clinical studies
Since 2024 launch
Would recommend to a friend
Every step of your journey is protected by medical-grade standards.
Based on published clinical literature. Individual results may vary depending on dosage and lifestyle factors.
* Assumes average height of 1.68m. Projections based on published clinical trial averages. Individual results vary.
Our patients are achieving life-changing results with protocol-guided tirzepatide therapy.
"I lost 19kg in 5 months. My doctor couldn't believe my bloodwork improvements. My energy levels are through the roof and I feel like myself again."
"As a busy professional, I needed something that works without complicated meal plans. Tirzepatide changed everything. Down 24kg and counting."
"The cold-chain delivery impressed me. Everything arrived perfectly. My cravings disappeared within the first two weeks. Best health decision I've ever made."
"I tried semaglutide before switching to tirzepatide. The difference is night and day. Lost 28kg total and my type 2 diabetes is now in remission."
From first consultation to your target weight, we guide you through every step.
Chat with our team on WhatsApp. We review your health history, goals, and determine if tirzepatide is right for you.
A licensed physician reviews your case and creates a personalized dosing protocol tailored to your body and target weight.
Your tirzepatide ships in temperature-controlled packaging to your door anywhere in Nigeria within 2-3 business days.
Weekly check-ins with your care team. Dosage adjustments as needed. We're with you until you reach your goal and beyond.
Everything you need to know about tirzepatide therapy in Nigeria.
Tirzepatide is a first-in-class dual GIP and GLP-1 receptor agonist. It works by activating two key metabolic pathways simultaneously: GIP helps regulate glucose metabolism and fat storage, while GLP-1 controls appetite and slows gastric emptying. This dual action provides superior efficacy compared to single-pathway therapies.
In published clinical trials, patients achieved significant body weight reduction over treatment periods. Individual results vary based on starting weight, dosage, diet, and activity level. Many of our Nigerian patients see significant results within the first 3 months.
Tirzepatide is clinically studied and has been extensively studied in clinical trials involving over 20,000 patients. Common side effects include mild nausea (which typically resolves after the first few weeks), reduced appetite, and occasional digestive changes. Our team start you on a low dose and gradually increase it to minimize side effects.
We use cold-chain logistics to maintain the medication at 2-8°C throughout transit. Orders are shipped in insulated packaging with gel ice packs via trusted courier partners (DHL, GIG Logistics). Lagos deliveries arrive within 24 hours; other states within 2-3 business days. All shipments are tracked and insured.
Yes. All our patients receive a prescription from a licensed physician after a thorough medical consultation. This ensures the therapy is safe and appropriate for you. The consultation is included in your treatment plan at no extra cost and can be done entirely via WhatsApp.
Ozempic and Wegovy contain semaglutide, which targets only the GLP-1 receptor. Tirzepatide targets both GIP and GLP-1 receptors, providing dual metabolic action. Published literature shows tirzepatide produced superior weight loss outcomes and better improvements in blood sugar control compared to single-pathway therapies. It's considered highly effective for weight management.
Join thousands of Nigerians achieving real, lasting weight loss with protocol-guided tirzepatide therapy.